ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 102,33
0,13%
Dow Jones
39 369,24
-0,76%
DAX
18 691,32
0,05%
Brent Oil
81,425
-0,13%
Bitcoin
68 060,02
-1,51%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Quince Therapeutics Inc (QNCX)

  7. Quince Therapeutics Inc (QNCX) Actualités

QNCX

Quince Therapeutics (QNCX)

Quince Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:QNCX
DateHeureSourceTitreSymboleSociété
13/05/202413h30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:QNCXQuince Therapeutics Inc
13/05/202413h00Business WireQuince Therapeutics Provides Business Update and Reports First Quarter 2024 Financial ResultsNASDAQ:QNCXQuince Therapeutics Inc
06/05/202422h05Business WireQuince Therapeutics to Present at The Citizens JMP Life Sciences ConferenceNASDAQ:QNCXQuince Therapeutics Inc
01/04/202413h00Business WireQuince Therapeutics Provides Business Update and Reports Fourth Quarter and Fiscal 2023 Financial ResultsNASDAQ:QNCXQuince Therapeutics Inc
22/02/202413h00Business WireQuince Therapeutics Launches Scientific Advisory BoardNASDAQ:QNCXQuince Therapeutics Inc
15/02/202422h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:QNCXQuince Therapeutics Inc
15/02/202413h00Business WireQuince Therapeutics Appoints Former Reata Pharmaceuticals Chief R&D Officer Dr. Rajiv Patni to its Board of DirectorsNASDAQ:QNCXQuince Therapeutics Inc
07/02/202422h05Business WireQuince Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences ConferenceNASDAQ:QNCXQuince Therapeutics Inc
02/02/202423h53Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:QNCXQuince Therapeutics Inc
05/01/202422h01Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:QNCXQuince Therapeutics Inc
04/01/202422h05Business WireQuince Therapeutics to Participate at Investor Events in January 2024NASDAQ:QNCXQuince Therapeutics Inc
25/10/202301h34Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:QNCXQuince Therapeutics Inc
23/10/202313h00Business WireQuince Therapeutics Completes Acquisition of EryDel S.p.A.NASDAQ:QNCXQuince Therapeutics Inc
28/09/202322h53Dow Jones NewsQuince Therapeutics to Advance Study of EryDex as FDA Lifts Application HoldNASDAQ:QNCXQuince Therapeutics Inc
28/09/202322h05Business WireU.S. FDA Partial Clinical Hold Lifted on IND for EryDel’s Lead Phase 3 Asset EryDex for the Treatment of Ataxia-TelangiectasiaNASDAQ:QNCXQuince Therapeutics Inc
06/09/202313h00Business WireQuince Therapeutics Appoints Dr. Charles S. Ryan as PresidentNASDAQ:QNCXQuince Therapeutics Inc
10/08/202322h05Business WireQuince Therapeutics to Present at Sidoti Virtual Investor Conference on August 17, 2023NASDAQ:QNCXQuince Therapeutics Inc
24/07/202323h56Business WireQuince Therapeutics rileva EryDel SpA e il suo asset di fase 3 mirato all'atassia-telangectasia, per cui attualmente non esistono trattamenti approvati, con opportunità stimate per un picco di vendite di oltre 1 miliardo di dollari USANASDAQ:QNCXQuince Therapeutics Inc
24/07/202313h00Business WireQuince Therapeutics to Acquire EryDel SpA and its Phase 3 Asset Targeting Ataxia-Telangiectasia with No Currently Approved Treatments and Estimated $1+ Billion Peak Sales OpportunityNASDAQ:QNCXQuince Therapeutics Inc
26/05/202323h51Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:QNCXQuince Therapeutics Inc
25/05/202322h26Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:QNCXQuince Therapeutics Inc
14/04/202322h13Edgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:QNCXQuince Therapeutics Inc
14/04/202322h07Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:QNCXQuince Therapeutics Inc
11/04/202313h00Business WireQuince Therapeutics Board of Directors Unanimously Rejects Unsolicited Proposal from Echo Lake CapitalNASDAQ:QNCXQuince Therapeutics Inc
06/04/202322h05Business WireQuince Therapeutics Engages MTS Health Partners as Independent Financial AdvisorNASDAQ:QNCXQuince Therapeutics Inc
05/04/202323h16Edgar (US Regulatory)Securities Registration (section 12(b)) (8-a12b)NASDAQ:QNCXQuince Therapeutics Inc
05/04/202322h05Business WireQuince Therapeutics Adopts Limited Duration Stockholders Rights PlanNASDAQ:QNCXQuince Therapeutics Inc
31/03/202322h01Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:QNCXQuince Therapeutics Inc
22/03/202310h00Business WireQuince Therapeutics Confirms Receipt of Unsolicited Acquisition Offer from Echo Lake CapitalNASDAQ:QNCXQuince Therapeutics Inc
21/03/202322h10AllPennyStocks.comAnother Biotech Massively Outperforms Broader EquitiesNASDAQ:QNCXQuince Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:QNCX

Dernières Valeurs Consultées

COIN
DIVIGBP
Divi
BIT
I09550
IT0005561664 20250915 13...
NASDAQ
SQFT
Presidio Property
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés